mo:re
Key Facts
| Invested since | 2025 |
| Based in | Hamburg |
About the company
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids accessible as a standard lab technique and providing verifiable results. The lab automation device covers all relevant process steps, setting a new benchmark for scalability, reproducibility, and standardization of 3D cell culture models.
Do you want to
know more about this company?
Zum Artikel
Dr. Christian Kannemeier Senior Investment Manager
Dr. Christian KannemeierSenior Investment Manager
mo:re in the news
More startups from Life Sciences
Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. …
To the complete profileof Nia Health
CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced …
To the complete profileof CereGate
Senostic is a diagnostics company developing a differential diagnostic test to detect multiple neurodegenerative diseases in a single test based on its proprietary SeedCylcer platform technology.
To the complete profileof SeNostic
Exit
Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune …
To the complete profileof Rigontec
GS Bavaria is the world‘s first supplier of nano- hard metal materials on industrial scale. Production is extremely cost-efficient, sustainable and comes with minimal energy consumption through our unique bioleaching …
To the complete profileof GS Bavaria
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
To the complete profileof WMT
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
To the complete profileof Refoxy Pharma
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
To the complete profileof Amal Therapeutics
Exit
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education …
To the complete profileof RIMASYS
smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …
To the complete profileof smartbax
Exit
Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for …
To the complete profileof Amedrix
Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX …
To the complete profileof Inovedis